{
    "cancer_info": {
        "cancer_name": "Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL)"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "CBC with peripheral smear",
            "Comprehensive metabolic panel (CMP)",
            "Serum quantitative immunoglobulins",
            "SPEP (serum protein electrophoresis)",
            "Serum immunofixation (SIFE)",
            "Serum viscosity testing (if symptomatic hyperviscosity suspected)",
            "β2-microglobulin",
            "LDH",
            "Uric acid",
            "Bone marrow aspirate/biopsy with IHC (CD19+, CD20+, sIgM+, CD5−/CD10−/CD23−)",
            "Flow cytometry (surface IgM+, CD79a+)",
            "MYD88 L265P mutation testing (PCR/NGS)",
            "CXCR4 mutation testing (if considering BTK inhibitors)",
            "CT chest/abdomen/pelvis (contrast-enhanced)",
            "FDG PET/CT",
            "Serum cryocrit",
            "Cold agglutinin testing",
            "Anti-MAG/GM1 antibodies (if neuropathy)",
            "Nerve conduction studies (NCS)",
            "Electromyography (EMG)",
            "Fat pad biopsy (for amyloidosis)",
            "CSF analysis (cytology, flow cytometry, MYD88 PCR for Bing-Neel)",
            "Brain/spine MRI (for Bing-Neel)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Asymptomatic",
            "risk_group": "Any",
            "treatment_plans": [
                {
                    "treatment_line": "Not applicable",
                    "patient_subgroup": "All asymptomatic patients",
                    "plan_name": "Observation",
                    "plan_details": "No treatment indicated for asymptomatic IgM elevation alone; active monitoring required",
                    "nccn_evidence_category": "Not applicable",
                    "nccn_recommendation_category": "Standard of care"
                }
            ]
        },
        {
            "staging_criteria": "Symptomatic",
            "risk_group": "Any",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "All eligible patients",
                    "plan_name": "Ibrutinib ± rituximab",
                    "plan_details": "BTK inhibitor-based therapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "All eligible patients",
                    "plan_name": "Zanubrutinib",
                    "plan_details": "Monotherapy BTK inhibitor (preferred over ibrutinib due to improved PFS/toxicity)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "All eligible patients",
                    "plan_name": "Bendamustine + rituximab (BR)",
                    "plan_details": "Chemoimmunotherapy combination",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "All eligible patients",
                    "plan_name": "Dexamethasone + rituximab + cyclophosphamide (DRC)",
                    "plan_details": "Immunochemotherapy regimen",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Other Recommended"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Rituximab-intolerant patients",
                    "plan_name": "Obinutuzumab substitution",
                    "plan_details": "Replaces rituximab in regimens",
                    "nccn_evidence_category": "Consensus-Based",
                    "nccn_recommendation_category": "Other Recommended"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Neuropathy patients",
                    "plan_name": "Bortezomib + rituximab + dexamethasone (BRD)",
                    "plan_details": "Proteasome inhibitor-based regimen (neuropathy-sparing considerations)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory",
            "risk_group": "Any",
            "treatment_plans": [
                {
                    "treatment_line": "Second-line or later",
                    "patient_subgroup": "Patients not receiving frontline BTK inhibitors",
                    "plan_name": "Ibrutinib or zanubrutinib",
                    "plan_details": "BTK inhibitor monotherapy or combination",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Second-line or later",
                    "patient_subgroup": "All eligible patients",
                    "plan_name": "Bendamustine + rituximab",
                    "plan_details": "Re-treatment option if initial response >2 years",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Second-line or later",
                    "patient_subgroup": "MYD88 WT/CXCR4 WHIM mutations",
                    "plan_name": "Venetoclax",
                    "plan_details": "BCL-2 inhibitor therapy",
                    "nccn_evidence_category": "Consensus-Based",
                    "nccn_recommendation_category": "Other Recommended"
                },
                {
                    "treatment_line": "Second-line or later",
                    "patient_subgroup": "Neuropathy considerations",
                    "plan_name": "Carfilzomib + rituximab + dexamethasone (CaRD)",
                    "plan_details": "Once weekly (preferred) or twice weekly dosing",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                },
                {
                    "treatment_line": "Second-line or later",
                    "patient_subgroup": "General population",
                    "plan_name": "Pirtobrutinib",
                    "plan_details": "BTK inhibitor option",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                }
            ]
        },
        {
            "staging_criteria": "Hyperviscosity Syndrome",
            "risk_group": "IgM >4,000 mg/dL",
            "treatment_plans": [
                {
                    "treatment_line": "Emergency",
                    "patient_subgroup": "Symptomatic patients",
                    "plan_name": "Plasmapheresis + rituximab-based therapy",
                    "plan_details": "Urgent plasmapheresis followed by systemic therapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Monitoring",
                    "patient_subgroup": "All patients on BTK inhibitors",
                    "plan_name": "IgM monitoring",
                    "plan_details": "Continued until next therapy to prevent IgM rebound",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard"
                }
            ]
        },
        {
            "staging_criteria": "Bing-Neel Syndrome (CNS Involvement)",
            "risk_group": "Confirmed CNS involvement",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "CNS involvement",
                    "plan_name": "Ibrutinib or zanubrutinib",
                    "plan_details": "Preferred CNS-penetrant BTK inhibitors",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Supplemental",
                    "patient_subgroup": "CNS involvement",
                    "plan_name": "Intrathecal methotrexate or radiotherapy",
                    "plan_details": "Adjunctive local therapies",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "MYD88 L265P: Diagnostic marker (>90% sensitivity); predicts response to BTK inhibitors",
            "CXCR4 mutations: Reduces depth/duration of BTK inhibitor response; associated with higher bone marrow disease burden",
            "Anti-MAG antibodies: Associated with IgM-related neuropathy; rituximab may improve symptoms",
            "Cryoglobulins/Cold agglutinins: Risk of hypervosity; requires warm sample processing for accurate IgM measurement",
            "IgM Levels: Correlates with tumor burden; hyperviscosity risk if >4 g/dL",
            "6q Deletion: Inferior overall survival; potential marker for targeted therapies"
        ]
    },
    "guideline_id": "（2025.V2）NCCN临床实践指南：巨球蛋白血症／淋巴浆细胞性淋巴瘤.txt"
}